[{"from": "human", "value": "Provide a description of this molecule. [C][C][=Branch1][C][=O][C][=C][C][=Branch2][Ring2][=Branch1][=C][Branch1][Branch1][C][=C][Ring1][=Branch1][O][C][C][C][N][C][C][C][Branch1][Branch1][C][C][Ring1][=Branch1][C][=N][O][C][=C][Ring1][Branch1][C][=C][C][=Branch1][Ring2][=C][Ring1][=Branch1][F][O][C]"}, {"from": "gpt", "value": "The molecule is an atypical antipsychotic for the treatment of schizophrenia symptoms. Hoechst Marion Roussel Inc. researched the drug until May 1996. In June 1997 they gave the research rights to Titan Pharmaceuticals, who gave the worldwide development, manufacturing, and marketing rights to Novartis in August 1998. On June 9, 2004, Titan Pharmaceuticals gave the Phase III development rights to Vanda Pharmaceuticals. FDA approved on May 9, 2009."}]